NCT01530529View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Healthy
Interventions
DRUG

PF-05180999

Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation

DRUG

PF-05180999

Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation

DRUG

PF-05180999

Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation

DRUG

PF-05180999

Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01530529 - A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999 | Biotech Hunter | Biotech Hunter